AUR-105
/ Dr. Reddy’s, Aurigene
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 17, 2026
SURYA-1: First in Human, Dose Escalation, Dose Expansion Study of AUR105
(clinicaltrials.gov)
- P1 | N=17 | Terminated | Sponsor: Aurigene Discovery Technologies Limited | N=40 ➔ 17 | Recruiting ➔ Terminated; Patient recruitment problems.
Enrollment change • First-in-human • Trial termination • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor
December 15, 2022
SURYA-1: First in Human, Dose Escalation, Dose Expansion Study of AUR105
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Aurigene Discovery Technologies Limited | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor
November 04, 2022
SURYA-1: First in Human, Dose Escalation, Dose Expansion Study of AUR105
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Aurigene Discovery Technologies Limited
New P1 trial • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1